Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Giving obese children weight-loss jabs is effective and helps prevent battles around mealtimes, researchers say. Experts at ...

Ozempic for diabetes management is being widely talked about for its weight loss benefits. But it can also have side effects.

Weight loss jabs like Wegovy combat several diverse conditions, from heart attacks to cancer, and the explanation may be that ...

The National Institute for Health and Care Excellence (Nice) previously stopped its appraisal of semaglutide (Wegovy) for use ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...